REGENXBIO Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data REGENXBIO Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	4.59	10.4	219	35.2	155	470	113	90.2	83.3	170
Cost of revenue	0.1	1.71	9.64	8.24	35.7	51.8	54.5	37.2	33.6
Gross profit	4.49	8.68	209	27	119	419	58.2	53	49.8
Research and development	45.5	57.2	83.9	124	166	181	242	232	209	228
General and administrative	23.6	27.2	36.9	51.8	63.8	79.3	85.3	88.5	76.6	82.9
Operating income	-65.3	-75.9	88.1	-149	-119	160	-263	-268	-233	-161
Interest expense					0.77	26.3	23.3	6.86	12.7	45
Interest income							5.5	9.1	12.1	12.2
Other non-operating income	1.94	2.72	16	51.5	13.2	-18.7	-17.5	4.48	6.24	-32.7
Pre-tax income	-63.4	-73.2	104	-97.5	-106	141	-280	-264	-227	-194
Income tax	-0.44	0	4.18	-2.76	5.24	13.4	-0.08	-0.15	0	0
Net income	-63	-73.2	99.9	-94.7	-111	128	-280	-263	-227	-194
EBITDA	-64.8	-73.2	92.1	-142	-111	170	-250	-251	-217	-146
EPS, basic	-2.38	-2.45	2.99	-2.58	-2.98	3.01	-6.50	-6.02	-4.59	-3.76
EPS, diluted	-2.38	-2.45	2.73	-2.58	-2.98	2.91	-6.50	-6.02	-4.59	-3.76
Shares, basic (weighted)	26.4	29.9	33.4	36.7	37.3	42.4	43.2	43.7	49.5	51.6
Shares, diluted (weighted)	26.4	29.9	36.6	36.7	37.3	43.9	43.2	43.7	49.5	51.6

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	24.8	46.7	75.6	69.5	338	345	97	34.5	57.5	34.5
Short-term investments	64.7	114	244	227	137	112	268	241	177	196
Receivables				38.1	43	32.4	28.1	24.8	20.5	26.4
Other current assets	1.01	1.41	3.83	4.2	1.95	10.2	9.35	20.4	13.8	12.9
Total current assets	93.4	168	338	345	531	519	416	335	278	281
Property, plant and equipment	9.32	14	28.7	29	56.5	132	142	132	118	105
Lease right-of-use assets				10.1	63.8	60.9	65.1	60.5	53.7	47.2
Long-term investments	69.4	15.6	151	104	46.8	392	201	38.9	10.2	10.8
Other non-current assets	0.4	0.86	2.32	4.56	5.28	6.43	6.4	4.81	4	4.61
Total assets	173	199	544	498	708	1,114	833	574	466	453
Accounts payable	1.54	4.83	4.41	6.41	10.6	11.4	27.2	22.8	22.8	21.4
Accrued liabilities	3.34	5.79	9.48	10.9	13.2	19.8	18.1	18.1	17.6	17.4
Deferred revenue			0.6		0.45	3.33	1.83	0.15	0.12	10.5
Total current liabilities	9.67	14.4	22.2	33.7	81.4	130	130	130	103	118
Lease liabilities				8.87	70.2	84.9	88.8	82.2	74.1	65.2
Other non-current liabilities			2.51	1.83	0.52	0.75	8.83	6.25	3.64	0.64
Total liabilities	11	15.6	35	47.7	330	350	317	262	206	350
Paid-in capital	276	371	593	628	667	928	973	1,021	1,193	1,229
Retained earnings	-115	-188	-83	-178	-289	-161	-442	-705	-932	-1,126
Other comprehensive income	-0.03	-0.72	-0.72	0.21	-0.36	-2.57	-15.4	-4.43	-0.74	-0.69
Shareholders' equity	162	183	509	450	378	764	516	312	260	103
Total equity	162	183	509	450	378	764	516	312	260	103
Total liabilities and equity	173	199	544	498	708	1,114	833	574	466	453
Shares outstanding	26.5	31.3	36.1	37	37.5	42.8	43.3	44	49.5	50.9

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-63	-73.2	99.9	-94.7	-111	128	-280	-263	-227	-194
Depreciation and amortization	0.54	2.69	3.98	7.15	8.41	9.56	12.9	17.3	16.2	15.6
Stock-based compensation	7.03	10.6	16.6	26.9	31.9	38.8	40.8	40.3	38.5	34.6
Deferred income tax	-0.44			-0.47
Change in receivables	1.07	0.56	-16.8	-8.62	-9.9	14.1	4.82	3.94	9.71	-7.66
Cash from operations	-48.6	-58	105	-108	-54.1	219	-207	-218	-173	-124
Capital expenditures	-8.15	-7.16	-13.3	-11.7	-26.9	-84.2	-30.7	-9.96	-2.44	-2.41
Purchases of investments	-45.1	-68.6	-446	-191	-123	-498	-185	-86.6	-190	-333
Sales and maturities of investments	72.6	70.2	180	290	233	170	203	285	290	319
Cash from investing	19.4	-4.79	-279	93.6	123	-407	-11.9	191	103	-15.9
Stock issued	0.18	82	190	7.06	5.62	4.28	2.8	1.52	1.51	0.32
Cash from financing	0.12	84.6	204	8.38	200	195	-28.8	-35	92.7	117
Net change in cash	-29.1	21.8	29.7	-5.77	269	7.48	-248	-62.4	23	-23.1
Free cash flow	-56.7	-65.2	91.4	-119	-80.9	135	-238	-228	-176	-126
Income taxes paid			3.44	0.9	-0.19	6	11.8	-0.14	-0.07	0.29

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $7.40 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Operating margin	-94.1%	Operating income / revenue.
EBITDA margin	-85.3%	EBITDA (operating income + depreciation and amortization) / revenue.
Net margin	-112.6%	Net income / revenue.
FCF margin	-143.1%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	-141.4%	Cash from operations / revenue.
Return on equity (ROE)	-273.7%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-50.8%	Net income / average total assets.
Return on invested capital (ROIC)	-367.6%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	131.3%	Research and development expense / revenue.
Stock-based pay / revenue	20.1%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.7%	Capital expenditures / revenue.
D&A / revenue	8.8%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	104.5%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	14.8%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	2.0%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-60.4%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-41.6%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-22.9%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-2.8%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-18.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-8.5%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	4.2%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	6.1%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	6.7%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.86x	Current assets / current liabilities.
Quick ratio	2.57x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	1.28x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	81.4%	Total liabilities / total assets.
Interest coverage	-3.91x	Operating income / interest expense.
Working capital	$153.5M	Current assets - current liabilities.
Tangible book value	$71.8M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.45x	Revenue / average total assets.
Fixed asset turnover	1.77x	Revenue / average property, plant and equipment.
Receivables turnover	1.63x	Revenue / average receivables.
Days sales outstanding	223 days	365 x average receivables / revenue.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$3.71	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$3.29	Revenue / diluted weighted shares.
FCF per share	-$4.71	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$4.65	Cash from operations / diluted weighted shares.
Book value per share	$1.32	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$1.32	Tangible book value / shares outstanding.
Cash per share	$1.95	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$488.5M	Share price x shares outstanding.
Enterprise value	$383.0M	Market cap + total debt - cash - short-term investments.
P/S	2.80x	Market cap / revenue.
P/B	6.81x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	6.81x	Market cap / tangible book value, when positive.
EV/Sales	2.19x	Enterprise value / revenue.
FCF yield	-51.1%	Free cash flow / market cap.
Earnings yield	-40.2%	Net income / market cap (the inverse of P/E).

What was REGENXBIO Inc.'s revenue in fiscal 2025?

REGENXBIO Inc. reported revenue of $170.4M for fiscal 2025, 104.5% higher than the year before.

Was REGENXBIO Inc. profitable in fiscal 2025?

No. It reported a net loss of $193.9M.

How much free cash flow did REGENXBIO Inc. generate in fiscal 2025?

Cash from operations of $124.0M minus capital expenditures of $2.4M left free cash flow of -$126.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to REGENXBIO Inc.